Harrison School of Pharmacy

Faculty and Staff Directory

Surachat Ngorsuraches

Surachat Ngorsuraches

Associate Professor
Department: Health Outcomes Research and Policy
Auburn University
Harrison School of Pharmacy
037 Foy Hall
Auburn, AL 36849
Email: surachat@auburn.edu
Phone: 334-844-8357
Fax: 334-844-8307


  • B.Sc., Pharmacy - Prince of Songkla University (Thailand), 1992
  • M.S., Social and Administrative Pharmacy - Wisconsin, 1999
  • Ph.D., Social and Administrative Pharmacy - Wisconsin, 2002

Research Interests:
  • Pharmaceutical Economics and Policy

Surachat Ngorsuraches,Ph.D. joined the Harrison School of Pharmacy in July, 2018 as an associate professor in the Department of Health Outcomes Research and Policy. He came to HSOP after four years as an associate professor in the Department of Pharmacy Practice at South Dakota State University.

Dr. Ngorsuraches earned a degree in pharmacy from Prince of Songkla University in Thailand in 1992. He completed both his masters and doctoral degrees in social and administrative pharmacy from the School of Pharmacy at the University of Wisconsin-Madison. Since that time, he has more than 15 years of experience in teaching, conducting research, and serving the pharmacy profession.

Recently, he received a research grant from the National Multiple Sclerosis Society (NMSS) to examine patients’ treatment preferences and their willingness-to-pay for disease-modifying therapies. He has also worked on engaging patients and their family members in patient-centered multiple sclerosis research for which he received a grant award from the Patient-Centered Outcomes Research Institute (PCORI).

Dr. Ngorsuraches has been an invited speaker to numerous professional meetings and is well-published in the area of pharmaceutical economics and policy research. He has been an active member of International Society of Pharmacoeconomics and Outcomes Research (ISPOR). He chaired the ISPOR Asia consortium and served as an executive board member for the consortium. Currently, he is a member of the ISPOR Health Science Policy Council and is a member of the Healthcare Provider Council with the National Multiple Sclerosis Society.

Selected Publications
  1. Kido K, Ngorsuraches S. Comparing Efficacy and Safety of Direct Oral Anticoagulations with Warfarin in the Mobidly Obese Population with Atrial Fibrillation. Ann Pharmacother (In press)
  2. Heiberger AL, Ngorsuraches S, Olgun G, Luze L, Leimbach C, Madison H, Lakhani SA. Safety and Effectiveness of Continuous Ketamine Infusion for Sedation in Mechanically Ventilated Pediatric Patients. Journal of Pediatric Pharmacology and Therapeutics (In press)
  3. Lebahn KK, Waybright RA, Ngorsuraches S, Johnson TJ. Role of Bedside Preparation in Reducing “Door-to-Needle” Tissue-Type Plasminogen Activator (Alteplase) Administration Times and Association with Patient Outcomes. S D Med (In press)
  4. Ngorsuraches S. Value-Based Pricing of Disease-Modifying Therapies for Multiple Sclerosis: Is This Mission Possible? S D Med 2018;71(3):134-135.
  5. Anderson SM, Beck B, Sterud S, Lockhorst R, Ngorsuraches S. Evaluation the Use of Appropriate Anticoagulation with Lenalidomide and Pomalidomide in Patients with Multiple Myeloma. J Oncol Pharm Pract 2018;Jan 1:1078155218758500. doi: 10.1177/1078155218758500. 
  6. Ngorsuraches S, Chaiyakunapruk N, Guo JJ, Yang B. Is It Time for Joint HTA in Asia? Opportunities and Challenges. Value Health Reg Issues 2017;12:99-100.
  7. Meyer BA, Seefeldt TM, Ngorsuraches S, Hendrickx LD, Lubeck PM, Farver DK, Heins JR. Interprofessional Education in Pharmacology Using High-Fidelity Simulation. Curr Pharm Teach Learn 2017;9(6):1055-1062.
  8. Ngorsuraches S, Mort JR. The Value of Subsidies of Health Plans and Cost Sharing for Prescription Drugs in Health Insurance Marketplace. Am Health Drug Benefits 2016;9(7):368-377.
  9. Sruamsiri R, Wagner AK, Ross-Degnan D, Lu CY, Dhippayom T, Ngorsuraches S, Chaiyakunapruk N. Expanding Access to High-Cost Medicines through The E2 Access Program in Thailand: Effects on Utilization, Health Outcomes and Cost using An Interrupted Time-Series Analysis. BMJ Open 2016;6(3):e008671. doi:10.1136/bmjopen-2015-008671.
  10. Wanishayakorn T, Sornlertlumvanich K, Ngorsuraches S. Benefit-Risk Assessment of HMG-CoA Reductase Inhibitors (Statins): A Discrete Choice Experiment. BMJ Open 2016;6(2):e009387. doi:10.1136/bmjopen-2015-009387.
  11. Wanishayakorn T, Ngorsuraches S. Benefit-Risk Assessment of Statins (Lipid Lowering Agents): A Multi-Criteria Decision Analysis. Journal of Multi-Criteria Decision Analysis 2016;23:28-39.doi:10.1002/mcda.1554.
  12. Ngorsuraches S, Nawanukool K, Petcharamanee K, Poopantrakool U. Patients’ Preferences and Willingness-to-Pay for Human Papilloma Virus Vaccines in Thailand. J Pharm Policy Pract 2015;8(1): 20.doi: 10.1186/s40545-015-0040-8
  13. Ngorsuraches S, Chaiyakan K. Equitable Prices of Single-Source Drugs in Thailand. Appl Health Econ Health Policy 2015;13(4):389-397.

Funded Research

Oregon Health & Science University
Drug effectiveness review project (DERP)
Role: Co-investigator
Total project funding awarded: $500,000

Patient-Centered Outcomes Research Institute
Engaging patients and their family members in patient-centered multiple sclerosis research
Role: Principle investigator
Total project funding awarded: $246,422

Sanford Health
Patient engagement in the management of multiple chronic conditions
Role: Principle investigator
Total project funding awarded: $1,000

National Multiple Sclerosis Society
Examining the cost-escalation and patient valuation of disease-modifying therapies for multiple sclerosis
Role: Principle investigator
Total project funding awarded: $117,878.20

Bristol-Myers Squibb
Understanding the current and potential impact of patient interaction toward personalized treatment pathways in melanoma
Role: Co-investigator
Total project funding awarded: $5,000 (South Dakota State University subcontract)

Last Updated: September 20, 2018